Article: P1.01 Development of a CLL-MRD staining protocol without the use of tandem dyes, and comparison with the ERIC 6-Color Protocol

Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer